Orthofix Medical Q1 sales beat estimates, reaffirms FY outlook

Orthofix Medical

05/05/2026 12:33

Overview

Medical technology firm's Q1 net sales rose, beating analyst expectations

Adjusted EBITDA for Q1 slightly missed analyst expectations

Company reaffirmed full-year 2026 financial guidance after spine channel actions

Outlook

Orthofix expects 2026 net sales between $850 mln and $860 mln

Company sees 2026 non-GAAP adjusted EBITDA of $95 mln to $98 mln

Orthofix expects positive free cash flow for 2026, excluding potential legal settlements

Result Drivers

DISTRIBUTOR TRANSITIONS - Co said Q1 reflected steady execution as it completed distributor transitions in spine, with further improvement expected as productivity increases

COMMERCIAL FOCUS - Growth in Global Spine Fixation driven by enhanced commercial focus, deeper procedural penetration, and benefits from distributor transition initiatives

DEMAND IN THERAPEUTIC SOLUTIONS AND LIMB RECONSTRUCTION - Therapeutic Solutions and Global Limb Reconstruction segments saw growth due to continued demand and effective commercial execution

Company press release: ID:nBw2Dn3nXa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$196.70 mln
$193.98 mln (5 Analysts)
Q1 EPS
-$0.52
Q1 Adjusted EBITDA
Slight Miss*
$9.70 mln
$9.72 mln (5 Analysts)
Q1 Gross Margin
70.90%


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Orthofix Medical Inc is $17.50, about 45.7% above its May 4 closing price of $12.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)